SCHEMBL197377

SCHEMBL197377

CCCCC(NO)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NOD1 Q9Y239 5/20 0.53
CA2 P00918 3/20 0.50
MAPK1 P28482 1/20 0.50
HDAC2 Q92769 1/20 0.45
CA1 P00915 1/20 0.45
GPR84 Q9NQS5 3/20 0.43
FFAR1 O14842 1/20 0.43
SLC1A3 P43003 1/20 0.42
SLC1A2 P43004 1/20 0.42
SLC1A1 P43005 1/20 0.42
MAPT P10636 1/20 0.42
LCK P06239 1/20 0.42
PPARD Q03181 1/20 0.42
ZDHHC20 Q5W0Z9 1/20 0.42
ZDHHC2 Q9UIJ5 1/20 0.42
SLC6A5 Q9Y345 1/20 0.42
MME P08473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL197378 1.00 NOD1 (0.53) NOD1CA2MAPK1HDAC2CA1
SCHEMBL198715 1.00 NOD1 (0.53) NOD1CA2MAPK1HDAC2CA1
SCHEMBL11057343 0.93 NOD1 (0.56) NOD1GPR84FFAR1SLC1A2SLC1A1
Sulfuric Acid SCHEMBL5549277 0.92 NOD1 (0.47) NOD1CA2MAPK1HDAC2CA1
SCHEMBL7100031 0.91 NOD1 (0.59) NOD1GPR84FFAR1MAPTLCK
SCHEMBL617558 0.86
SCHEMBL1604327 0.86
SCHEMBL2172011 0.86
SCHEMBL6238817 0.84 CA2 (0.52) NOD1CA2MAPK1HDAC2CA1
Butane SCHEMBL15570208 0.84 HDAC1 (0.48) NOD1CA2MAPK1HDAC2GPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1105416-A1 NOVEL PROCESS FOR THE SYNTHESIS OF EXOCHELINS Keystone Biomedical, Inc. (US) 2001-06-13 EP claimed
US-6063919-A ESTERIFICATION OF O-DEPROTECTED DIBENZYL EXOCHELIC ACID WITH BENZYL EPI-COBACTIN, HYDROGENOLYTICALLY REMOVING THE THREE BENZYL GROUPS TO FORM EXOCHELIN 786SM(R) KEYSTONE BIOMEDICAL, INC. (US) 2000-05-16 US claimed
WO-2000009547-A1 NOVEL PROCESS FOR THE SYNTHESIS OF EXOCHELINS KEYSTONE BIOMEDICAL, INC. (US) 2000-02-24 WO claimed
US-20260048158-A1 B7-H3 MINIPROTEINS, CONJUGATES, AND USES THEREOF AKTIS ONCOLOGY INC (US) 2026-02-19 US disclosed
US-12427212-B2 Nectin-4 binding miniproteins, conjugates and uses thereof AKTIS ONCOLOGY, INC. (US) 2025-09-30 US disclosed
US-20250242065-A1 MINIPROTEINS, CONJUGATES & USES THEREOF AKTIS ONCOLOGY, INC. 2025-07-31 US disclosed
US-20250223627-A1 FLUOROGENIC SUBSTRATES FOR AMINOPEPTIDASE DETECTION IN BIOFLUIDS Sunbird Bio, Inc. 2025-07-10 US disclosed
WO-2025122976-A1 B7-H3 MINIPROTEINS, CONJUGATES, AND USES THEREOF AKTIS ONCOLOGY, INC. (US) 2025-06-12 WO disclosed
US-20220204457-A1 ARGININE GINGIPAIN INHIBITORS CORTEXYME INC (US) 2022-06-30 US disclosed
EP-3941586-A1 ARGININE GINGIPAIN INHIBITORS Cortexyme, Inc. (US) 2022-01-26 EP disclosed
CN-113825542-A Arginine gum protease inhibitors 库特克希米公司 2021-12-21 CN disclosed
WO-2000009547-A1 NOVEL PROCESS FOR THE SYNTHESIS OF EXOCHELINS KEYSTONE BIOMEDICAL, INC. (US) 2000-02-24 WO disclosed
EP-0938475-A1 PIPERIDINE COMPOUNDS GILEAD SCIENCES, INC. (US) 1999-09-01 EP disclosed
WO-1998017647-A1 PIPERIDINE COMPOUNDS GILEAD SCIENCES, INC. (US) 1998-04-30 WO disclosed
EP-0807118-A2 NOVEL COMPOUNDS AND METHODS FOR MAKING AND USING SAME GILEAD SCIENCES, INC. (US) 1997-11-19 EP disclosed
EP-0759917-A1 NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES GILEAD SCIENCES, INC. (US) 1997-03-05 EP disclosed
WO-1996026933-A9 NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES 1996-11-28 WO disclosed
WO-1996023801-A2 NOVEL COMPOUNDS AND METHODS FOR MAKING AND USING SAME GILEAD SCIENCES, INC. (US) 1996-08-08 WO disclosed
EP-0719273-A1 NUCLEOTIDE ANALOGS GILEAD SCIENCES, INC. (US) 1996-07-03 EP disclosed
WO-1995007920-A1 NUCLEOTIDE ANALOGS GILEAD SCIENCES, INC. (US) 1995-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220204457-A1 ARGININE GINGIPAIN INHIBITORS ARGLU1, PADI1, ARG1 NOD1 3141/4885CA2 686/4885MAPK1 1610/4885
US-20250242065-A1 MINIPROTEINS, CONJUGATES & USES THEREOF NECTIN4, CD2BP2, HAVCR2 NOD1 2328/4885CA2 4494/4885MAPK1 4681/4885
US-12427212-B2 Nectin-4 binding miniproteins, conjugates and uses thereof NECTIN4, CD2BP2, HAVCR2 NOD1 1518/4885CA2 4457/4885MAPK1 4300/4885
US-20260048158-A1 B7-H3 MINIPROTEINS, CONJUGATES, AND USES THEREOF MICA, CD274, JMJD6 NOD1 3318/4885CA2 4630/4885MAPK1 3759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.